News

The Manila Times1d

Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference

Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the Company’s lead pan-viral protease inhibitor ...
TipRanks on MSN1d

Cocrystal Pharma showcases CDI-988, antiviral for norovirus infection

Cocrystal Pharma (COCP) announces that President and co-CEO Sam Lee, PhD discussed the scientific foundation and clinical progress with the ...

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against ...
New Scientist3d

Antibody cocktail could work as a universal flu treatment

A mix of three antibodies seems to protect mice against several strains of influenza and could one day be useful against ...

Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and ...

There are currently no approved vaccines or treatments for norovirus infectionCocrystal’s CDI-988 is the first antiviral for the potential ...